The Prevention of New Sensitizations by Specific Immunotherapy: A Long-Term Observational Case Control Study
- *Corresponding Author:
- Andrzej Bozek
Clinical Department of Internal Medicine, Dermatology and Allergology
Medical University of Silesia, M. Sklodowskiej-Curie 1041-800 Zabrze, Poland
E-mail: [email protected]
Received date: June 06, 2013; Accepted date: July 11, 2014; Published date: July 18, 2014
Citation: Bozek A, Gawlik R, Jarzab J (2014) The Prevention of New Sensitizations by Specific Immunotherapy: A Long-Term Observational Case Control Study. J Allergy Ther 5:182. doi: 10.4172/2155-6121.1000182
Copyright: © 2014 Bozek A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Some studies have indicated that allergen specific immunotherapy (SIT) may prevent new sensitizations to other inhalant allergens; however, there are only a few longitudinal observations that have explored this event. The aim of this study was to perform a 20 year post-SIT observational analysis to assess the appearance of new sensitizations in SIT patients compared with non-SIT patients.
Material and methods: In total, 1,420 atopic bronchial asthma or/and allergic rhinitis patients (701 women and 719 men) with a mean age of 21.2 ± 9.2 years (at the time when the SIT concluded) were evaluated twenty years after their immunotherapies. New sensitization cases were determined by evaluating skin prick tests, allergen specific IgE and the clinical symptoms that were evaluated prior to and 5, 10, 15 and 20 years after SIT. The SIT group was compared with a control group consisting of 1,254 allergic patients who had never received SIT and had only received symptomatic treatments.
Results: After 20 years, 301 (21.2%) patients in the 4-5 year SIT group showed a new sensitization compared with 509 (40.6%) control group patients (p=0.004). In monosensitized SIT patients (n=886), there were significantly more new sensitizations in the control group (n=624): 69 (7.8%) vs. 195 (31.3%) (p=0.001). The odds ratio of the post-SIT new sensitization incidence in the whole group was 0.76 (95% CI: 0.55-0.92), whereas it was 1.32 in the control group (95% CI: 1.22-1.45).
Conclusion: The obtained data suggests a preventive role for specific immunotherapy in new sensitizations, especially in monosensitized patients.